Does Rezdiffra Cause Weight Loss? What the Research Says

Rezdiffra (resmetirom) was approved in 2024 for a specific type of liver disease called NASH (nonalcoholic steatohepatitis). Weight loss is not a primary intended effect of this medication. Current research shows weight changes are modest and inconsistent, averaging 2-5 pounds in clinical trials. This is not a weight loss drug. If you take Rezdiffra hoping to drop significant weight, you will likely be disappointed.

Does Rezdiffra Cause Weight Loss?

The short answer is no, not in a meaningful or reliable way. In the MAESTRO-NASH phase 3 trial, patients taking Rezdiffra lost an average of about 2-3% of their body weight over 52 weeks. For a 200-pound person, that is roughly 4-6 pounds. The placebo group lost about 1-2% on average. The difference between the two groups was small.

Some patients did lose more weight, but this was not consistent. The drug did not cause weight loss as a direct effect. The small weight changes seen may be related to improvements in liver function or other metabolic shifts. But Rezdiffra is not designed or approved for weight management.

If you are taking Rezdiffra and lose weight, it is likely modest. Do not expect dramatic changes. If you are not losing weight, that is normal too. The drug works on liver scarring and inflammation, not on fat tissue directly.

What Is Rezdiffra and How Does It Work?

Rezdiffra is a thyroid hormone receptor beta agonist. That is a mouthful. In simpler terms, it targets a specific receptor in the liver that helps regulate how the liver processes fat. The drug reduces fat buildup in the liver and slows down scarring (fibrosis).

This is important because NASH is a condition where fat builds up in the liver, causing inflammation and damage. Over time, this can lead to cirrhosis and liver failure. Rezdiffra is the first FDA-approved drug specifically for NASH with moderate to advanced scarring.

The drug does not directly burn fat or suppress appetite. It works on liver metabolism. Some early research suggested thyroid hormone receptor activation could increase metabolic rate slightly, but this effect is minimal at the doses used for NASH. The drug was designed to fix the liver, not to change your weight.

What Does the Research on Rezdiffra and Weight Loss Show?

The main study, called MAESTRO-NASH, included over 900 patients. Researchers measured liver scarring, inflammation, and fat content. Weight was tracked as a secondary measure, not a primary goal.

At 52 weeks, patients on 80 mg of Rezdiffra lost an average of 2.5% of body weight. Those on 100 mg lost about 3.2%. The placebo group lost 1.5%. So the drug group lost about 1-2% more than placebo. That is statistically significant but clinically modest.

A 2025 analysis of the same trial data looked at weight changes more closely. About 15% of patients on Rezdiffra lost more than 5% of their body weight. That is roughly 10 pounds for a 200-pound person. But 85% of patients did not reach that level. For comparison, typical weight loss drugs like semaglutide (Wegovy) produce 10-15% weight loss in most patients.

The weight loss seen with Rezdiffra is closer to what you might get from lifestyle changes alone. It is not in the same category as dedicated weight loss medications.

How Does Rezdiffra Compare to Weight Loss Medications?

This comparison matters because some people confuse Rezdiffra with drugs like Ozempic or Mounjaro. They work differently. Here is a simple table:

Rezdiffra is not a weight loss drug. If you need to lose weight for liver health, you should not rely on Rezdiffra alone. Lifestyle changes or dedicated weight loss medications are far more effective.

Can Rezdiffra Help With Weight Loss Indirectly?

There is a possible indirect effect. If Rezdiffra reduces liver inflammation and improves liver function, your body may process nutrients better. Some patients report feeling less bloated or having more energy. This could support weight loss efforts, but the drug itself does not cause it.

Another indirect effect: Rezdiffra may improve insulin sensitivity. Better insulin control can make it easier to lose weight. But again, this is a secondary benefit, not a primary effect. The magnitude of improvement is small compared to lifestyle changes or diabetes medications.

Some people report reduced cravings or appetite changes on Rezdiffra. Current research does not support this as a consistent effect. A few patients in trials mentioned appetite changes, but it was not common enough to be a reported side effect. As of 2026, there is no evidence that Rezdiffra directly suppresses appetite.

What Are the Side Effects of Rezdiffra?

Rezdiffra has side effects, and some can affect weight indirectly. The most common side effects include diarrhea, nausea, and abdominal pain. About 10-15% of patients in trials reported diarrhea. This could cause temporary weight loss due to fluid loss, but that is not healthy weight loss.

Other side effects include headache, fatigue, and changes in thyroid hormone levels. The drug can increase T4 and decrease TSH in some patients. This is usually mild and does not cause symptoms. But thyroid changes could theoretically affect metabolism. In practice, the effect is too small to matter for weight.

Serious side effects are rare but include gallbladder issues and liver enzyme elevations. The drug requires regular blood monitoring. Weight loss from side effects like diarrhea is not a benefit. It is a sign your body is not tolerating the drug well.

Who Should Take Rezdiffra?

Rezdiffra is for adults with NASH and moderate to advanced liver fibrosis (stage F2 or F3). It is not for people with fatty liver without scarring (simple steatosis). It is not for weight loss. Your doctor will confirm NASH with a liver biopsy or non-invasive tests before prescribing.

The drug costs about $40,000 per year without insurance. Insurance coverage is limited to people with confirmed NASH and fibrosis. You cannot get it for weight loss alone. Even if you have NASH, weight loss is still recommended as the first treatment.

If you have NASH, losing 7-10% of your body weight through diet and exercise is more effective than Rezdiffra at reducing liver fat and inflammation. The drug is an add-on, not a replacement. Most patients are advised to continue lifestyle changes while taking Rezdiffra.

What Should You Do If You Want to Lose Weight With NASH?

Focus on what works. The strongest evidence for NASH improvement is weight loss through calorie restriction and exercise. Losing 5-7% of body weight reduces liver fat. Losing 10% or more can reverse early scarring.

A Mediterranean diet has the most research support for liver health. It emphasizes vegetables, fruits, whole grains, lean protein, and healthy fats. Limit added sugars, refined carbs, and processed foods. Avoid sugary drinks entirely.

Exercise helps even without weight loss. Aerobic exercise and resistance training both reduce liver fat. Aim for 150 minutes of moderate activity per week. Walking, cycling, swimming, or strength training all work.

If you cannot lose weight through lifestyle alone, ask your doctor about weight loss medications. GLP-1 drugs like semaglutide have shown promise for NASH in early trials. They are not FDA-approved for NASH yet, but they are approved for weight management. Some doctors prescribe them off-label for NASH.

Frequently Asked Questions About Rezdiffra and Weight Loss